Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,699
Out of 5,064 analysts
69
Total ratings
33.96%
Success rate
-7.53%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $6.77 | +180.65% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.75 | +431.21% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $11.80 | +281.36% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $70.87 | -57.67% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $755.90 | +25.68% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.80 | +622.22% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $68.11 | -32.46% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $30.71 | +124.68% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $4.87 | +64.27% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $12.24 | +14.38% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $15.87 | +265.47% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $17.00 | +311.76% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.23 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $65.44 | -3.73% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.25 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.17 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $79.66 | -18.40% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $337.54 | -24.45% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.18 | +665.55% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $203.90 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $6.77
Upside: +180.65%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.75
Upside: +431.21%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $11.80
Upside: +281.36%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $70.87
Upside: -57.67%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $755.90
Upside: +25.68%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.80
Upside: +622.22%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $68.11
Upside: -32.46%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $30.71
Upside: +124.68%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $4.87
Upside: +64.27%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $12.24
Upside: +14.38%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $15.87
Upside: +265.47%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $17.00
Upside: +311.76%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.23
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $65.44
Upside: -3.73%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $46.25
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $79.66
Upside: -18.40%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $337.54
Upside: -24.45%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.18
Upside: +665.55%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $203.90
Upside: -